Literature DB >> 19809274

Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts.

I-Wei Chang1, Hsuan-Ying Huang, Ming-Tse Sung.   

Abstract

Melanotic Xp11 translocation renal cancer is a recently recognized aggressive epithelioid neoplasm with features overlapping between PEComa, carcinoma, and melanoma. We describe morphologic and immunohistochemical characteristics of a melanotic Xp11 translocation renal cancer occurring in an 18-year-old girl and perform molecular genetic studies to analyze its genetic alterations and related melanogenetic activities. The tumor was composed of solid nests of epithelioid cells bearing abundant clear to finely granular eosinophilic cytoplasm and separated by delicate vascular septa. Finely granular and nonrefractile brown melanin pigments, highlighted by Fontana-Masson stain, were scattered through the tumor. By immunohistochemistry, the tumor was diffusely and strongly labeled by TFE3 and focally stained by HMB45 in a patchy pattern. In contrast, all other applied immunomarkers, including cytokeratins, epithelial membrane antigen, vimentin, CD10, S-100, smooth muscle actin, desmin, c-kit, CD68, and microphthalmia-associated transcription factor, were nonreactive to the tumor. Reverse transcription-polymerase chain reaction and validating sequencing demonstrated PSF-TFE3 gene fusion, a novel exon composition juxtaposing PSF exon 9 to TFE3 exon 5. Up-regulations of melanogenesis-associated regulators, including microphthalmia-associated transcription factor, tyrosinase (TYR), and tyrosinase-related protein 1 (TYRP1), were identified in the tumor by semiquantitative reverse transcription-polymerase chain reaction. The morphologic and immunohistochemical discrepancies between this intriguing melanotic tumor and other documented renal cell carcinomas bearing identical PSF-TFE3 gene fusion may suggest melanotic Xp11 translocation renal cancer is a distinct entity among the MiT/TFE family neoplasms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19809274     DOI: 10.1097/PAS.0b013e3181ba7a5f

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  Translocation renal cell carcinomas in adults: a single-institution experience.

Authors:  Minghao Zhong; Patricia De Angelo; Lisa Osborne; Alberto E Paniz-Mondolfi; Matthew Geller; Youfeng Yang; W Marston Linehan; Maria J Merino; Carlos Cordon-Cardo; Dongming Cai
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

2.  Xp11.2 translocation renal cell carcinoma with PSF-TFE3 rearrangement.

Authors:  Minghao Zhong; Paul Weisman; Bing Zhu; Maria Brassesco; Youfeng Yang; W Marston Linehan; Maria J Merino; David Zhang; Stephen Rohan; Dongming Cai; Ximing Yang
Journal:  Diagn Mol Pathol       Date:  2013-06

Review 3.  Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.

Authors:  Eric C Kauffman; Christopher J Ricketts; Soroush Rais-Bahrami; Youfeng Yang; Maria J Merino; Donald P Bottaro; Ramaprasad Srinivasan; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2014-07-22       Impact factor: 14.432

4.  Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.

Authors:  Malcolm Hayes; Kvetoslava Peckova; Petr Martinek; Milan Hora; Kristyna Kalusova; Lubomir Straka; Ondrej Daum; Bohuslava Kokoskova; Pavla Rotterova; Kristyna Pivovarčikova; Jindrich Branzovsky; Magdalena Dubova; Pavla Vesela; Michal Michal; Ondrej Hes
Journal:  Virchows Arch       Date:  2014-12-28       Impact factor: 4.064

5.  TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis.

Authors:  J Kenneth Schoolmeester; Linda N Dao; William R Sukov; Lu Wang; Kay J Park; Rajmohan Murali; Meera R Hameed; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2015-03       Impact factor: 6.394

6.  Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.

Authors:  Ming-Mo Hou; Jia-Juan Hsieh; Nai-Jen Chang; Hsuan-Ying Huang; Hung-Ming Wang; Cheng-Keng Chuang; Todd Hsu; John Wen-Cheng Chang
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

7.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

8.  A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.

Authors:  Aiko Kurisaki-Arakawa; Tsuyoshi Saito; Michiko Takahashi; Keiko Mitani; Yuki Fukumura; Yoji Nagashima; Pedrum Argani; Takashi Yao
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

Review 9.  Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas.

Authors:  Qiu Rao; Qiu-Yuan Xia; Liang Cheng; Xiao-Jun Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

Review 10.  A review of neoplasms with MITF/MiT family translocations.

Authors:  Shuanzeng Wei; Joseph R Testa; Pedram Argani
Journal:  Histol Histopathol       Date:  2022-02-02       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.